Persistent altered fusion transcript splicing identifies RUNX1-RUNX1T1+ AML patients likely to relapse

European Journal of Haematology

Volumn 84, Issue 2, 2010, Pages 128-132

  Ommen, Hans B ^a   Østergaard, Mette ^a   Yan, Ming ^b   Brændstrup, Karin ^a   Zhang, Dong Er ^b   Hokland, Peter ^a  

^a AARHUS UNIVERSITY HOSPITAL   (Denmark)

^b UNIVERSITY OF CALIFORNIA SAN DIEGO   (United States)

Author keywords

Acute myeloid leukemia; Alternative splicing; Leukemogenesis; RUNX1 RUNX1T1

Indexed keywords

HYBRID PROTEIN; MESSENGER RNA; TRANSCRIPTION FACTOR; TRANSCRIPTION FACTOR RUNX1; TRANSCRIPTION FACTOR RUNX1T1; UNCLASSIFIED DRUG;

ACUTE GRANULOCYTIC LEUKEMIA; ADOLESCENT; ADULT; ALTERNATIVE RNA SPLICING; ARTICLE; BLOOD DONOR; CANCER PATIENT; CANCER REGRESSION; CANCER RELAPSE; CHILD; CLINICAL ARTICLE; CONTROLLED STUDY; EXON; FOLLOW UP; GENE FUSION; GENETIC VARIABILITY; HIGH RISK PATIENT; HUMAN; HUMAN CELL; HUMAN TISSUE; LEUKEMOGENESIS; PREDICTOR VARIABLE; PRIORITY JOURNAL; RISK ASSESSMENT;

ADOLESCENT; ADULT; ANIMALS; BASE SEQUENCE; CHILD; CHILD, PRESCHOOL; CORE BINDING FACTOR ALPHA 2 SUBUNIT; EXONS; FEMALE; FOLLOW-UP STUDIES; HUMANS; LEUKEMIA, MYELOID, ACUTE; MALE; MICE; MIDDLE AGED; ONCOGENE PROTEINS, FUSION; PROTO-ONCOGENE PROTEINS; RECURRENCE; REMISSION INDUCTION; RNA SPLICING; RNA, MESSENGER; RNA, NEOPLASM; SEQUENCE DELETION; TRANSCRIPTION FACTORS;

EID: 74049159886     PISSN: 09024441     EISSN: 16000609     Source Type: Journal    
DOI: 10.1111/j.1600-0609.2009.01371.x     Document Type: Article

References (17)

1. Estey E, Dohner H. Acute myeloid leukaemia. Lancet 2006 368 : 1894 1907.
2. Grimwade D, Walker H, Oliver F, et al. The importance of diagnostic cytogenetics on outcome in AML: analysis of 1,612 patients entered into the MRC AML 10 trial. The Medical Research Council Adult and Children's Leukaemia Working Parties. Blood 1998 92 : 2322 2333.
3. Yan M, Kanbe E, Peterson LF, et al. A previously unidentified alternatively spliced isoform of t(8;21) transcript promotes leukemogenesis. Nat Med 2006 12 : 945 949.
4. Higuchi M, O'Brien D, Kumaravelu P, Lenny N, Yeoh EJ, Downing JR. Expression of a conditional AML1-ETO oncogene bypasses embryonic lethality and establishes a murine model of human t(8;21) acute myeloid leukemia. Cancer Cell 2002 1 : 63 74.
5. Rhoades KL, Hetherington CJ, Harakawa N, Yergeau DA, Zhou L, Liu LQ, Little MT, Tenen DG. Analysis of the role of AML1-ETO in leukemogenesis, using an inducible transgenic mouse model. Blood 2000 96 : 2108 2115.
6. Jurlander J, Caligiuri MA, Ruutu T, et al. Persistence of the AML1/ETO fusion transcript in patients treated with allogeneic bone marrow transplantation for t(8;21) leukemia. Blood 1996 88 : 2183 2191.
7. Miyamoto T, Nagafuji K, Akashi K, Persistence of multipotent progenitors expressing AML1/ETO transcripts in long-term remission patients with t(8;21) acute myelogenous leukemia. Blood 1996 87 : 4789 4796.
8. Peterson LF, Boyapati A, Ahn EY, Biggs JR, Okumura AJ, Lo MC, Yan M, Zhang DE. Acute myeloid leukemia with the 8q22;21q22 translocation: secondary mutational events and alternative t(8;21) transcripts. Blood 2007 110 : 799 805.
9. Wolford JK, Prochazka M. Structure and expression of the human MTG8/ETO gene. Gene 1998 212 : 103 109.
10. Ostergaard M, Olesen LH, Hasle H, Kjeldsen E, Hokland P. WT1 gene expression: an excellent tool for monitoring minimal residual disease in 70% of acute myeloid leukaemia patients - results from a single-centre study. Br J Haematol 2004 125 : 590 600.
11. Ommen HB, Nyvold CG, Braendstrup K, Andersen BL, Ommen IB, Hasle H, Hokland P, Ostergaard M. Relapse prediction in acute myeloid leukaemia patients in complete remission using WT1 as a molecular marker: development of a mathematical model to predict time from molecular to clinical relapse and define optimal sampling intervals. Br J Haematol 2008 141 : 782 791.
12. Stentoft J, Hokland P, Ostergaard M, Hasle H, Nyvold CG. Minimal residual core binding factor AMLs by real time quantitative PCR - initial response to chemotherapy predicts event free survival and close monitoring of peripheral blood unravels the kinetics of relapse. Leuk Res 2006 30 : 389 395.
13. Kozu T, Fukuyama T, Yamami T, Akagi K, Kaneko Y. MYND-less splice variants of AML1-MTG8 (RUNX1-CBFA2T1) are expressed in leukemia with t(8;21). Genes Chromosomes Cancer 2005 43 : 45 53.
14. Lafiura KM, Edwards H, Taub JW, Matherly LH, Fontana JA, Mohamed AN, Ravindranath Y, Ge Y. Identification and characterization of novel AML1-ETO fusion transcripts in pediatric t(8;21) acute myeloid leukemia: a report from the Children's Oncology Group. Oncogene 2008 27 : 4933 4942.
15. Jiao B, Wu CF, Liang Y, et al. AML1-ETO9a is correlated with C-KIT overexpression/mutations and indicates poor disease outcome in t(8;21) acute myeloid leukemia-M2. Leukemia 2009 23 : 1598 1604.
16. Wang YY, Zhou GB, Yin T, et al. AML1-ETO and C-KIT mutation/ overexpression in t(8;21) leukemia: implication in stepwise leukemogenesis and response to Gleevec. Proc Natl Acad Sci USA 2005 102 : 1104 1109.
17. Tobal K, Newton J, Macheta M, Chang J, Morgenstern G, Evans PA, Morgan G, Lucus GS, Liu Yin JA. Molecular quantitation of minimal residual disease in acute myeloid leukemia with t(8;21) can identify patients in durable remission and predict clinical relapse. Blood 2000 95 : 815 819.